Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.39 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3588948 | 0.87 | MEN1 (0.48) | MEN1KMT2ANR4A2MRGPRX4NR4A1 | |
| SCHEMBL3598854 | 0.82 | MAOB (0.39) | CA1MAOBTACR1 | |
| SCHEMBL3605126 | 0.81 | PLA2G2A (0.40) | MEN1KMT2AGCK | |
| SCHEMBL20259514 | 0.80 | MAOB (0.46) | CA1MAOBTACR1 | |
| SCHEMBL3607194 | 0.80 | KMT2A (0.35) | MEN1KMT2AMRGPRX4 | |
| SCHEMBL3605804 | 0.80 | PLA2G2A (0.35) | MEN1KMT2A | |
| SCHEMBL1427178 | 0.79 | MEN1 (0.64) | MEN1KMT2ANR4A2MRGPRX4NR4A1 | |
| SCHEMBL3603264 | 0.78 | PLA2G2A (0.35) | MEN1KMT2AMRGPRX4 | |
| SCHEMBL14251338 | 0.76 | MEN1 (0.79) | MEN1KMT2ANR4A2MRGPRX4NR4A1 | |
| SCHEMBL5184267 | 0.75 | KMT2A (0.58) | MEN1KMT2ANR4A2MRGPRX4NR4A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700640-B2 | Process for making phenoxy benzamide compounds | ASTRAZENECA AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | ASTRAZENECA AB (SE) | 2008-08-21 | — | — | US | disclosed |
| EP-1802570-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | AstraZeneca AB (SE) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006040527-A1 | PROCESS FOR MAKING PHENOXY BENZAMIDE COMPOUNDS | ASTRAZENECA AB (SE) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200694-A1 | Process for Making Phenoxy Benzamide Compounds | PAH, MAOB, TYR | MEN1 2346/4885KMT2A 726/4885NR4A2 2786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.